Impact of Hypertonic Saline Solution on Acute Decompensated Heart Failure — HSS  

Acute Decompensated Heart Failure Clinical Trial

Official title: Impact of Hypertonic Saline Solution on Acute Decompensated Heart Failure

Status Recruiting

Clinical Trial Summary

Acute decompensated heart failure (HF) is one of the most common cardiologic issues in emergency departments.

Loop diuretics have long been recognized as the key for the treatment of Acute Decompensated Heart Failure (ADHF).However, chronic treatment with diuretics may limit their response and deteriorates the renal function. The hypertonic saline solution (HSS) has been proposed in recent years as an adjunctive therapy for intravenous loop diuretics to improve or restore their initial pharmacological efficacy.

In this study the investigators will evaluate the effectiveness of HSS as an adjunct to i.v. furosemide in patients admitted for AHF with renal dysfunction

Clinical Trial Description

In the era of the emergence of novel therapies for advanced Chronic Heart Failure , the use of HSS as a therapeutic adjunct to i.v. loop diuretics still needs to be explored on a larger scale, in particular in patients with renal dysfunction.

The objective of this study is: to evaluate the effectiveness of HSS as an adjunct to i.v. furose¬mide in patients admitted for AHF with renal dysfunction.

• Patients receive intravenous infusion of HSS (50ml of 10% NaCl) + Furosemide ( 250mg of furosemide) administered over one hour twice a day.

• Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day. ;

Related Conditions & MeSH terms

• Acute Decompensated Heart Failure
• Heart Failure

• NCT number: NCT05298098
• Study type: Interventional
• Source: University of Monastir
• Contact: Semir Nouira, Professor
• Phone: 73106046
• Email: semir.nouira@rns.tn
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2018
• Completion date: September 2023